Cytotoxic effects of 4-{3-[5-(n-tolyl)isoxazol-3-yl)ureido)butanoic acid, cisplatin and their combination in vitro and in vivo

A. N. Chernov; L. V. Pozdniak

doi:undefined

Cytotoxic effects of 4-{3-[5-(n-tolyl)isoxazol-3-yl)ureido)butanoic acid, cisplatin and their combination in vitro and in vivo

A. N. Chernov, L. V. Pozdniak

Full Text:

PDF (Rus) |

Generate QR code

Abstract

In experiments on Ehrlich's ascitic carcinoma cell culture in mice tumor-bearers, the cytotoxic action of heterocyclic compound PS 1603 (4-{3-[5-(n-tolyl)isoxazol-3-yl)ureido)butanoic acid, cisplatin and their combination on the mitogenic activity, the cell death (in vitro), the tumor mass, and the animals' lifetime (in vivo) has been studied. It has been established that PS 1603 has a minor (in vitro) and mild (in vivo) antitumoral effect. The combination of a heterocyclic compound and a chemo-therapeutic agent in a ten-fold reduced dose decreases the expressed effects of a cytostatic agent in concentrations close to clinical ones but does not intensify them.

References

1. Bozhkova V. P., Brezhestovskii P. D., Buravlev V. P. i dr. Rukovodstvo po kul'tivirovaniyu nervnoi tkani. M., 1988.

2. Gorin B. I. Obshchaya organicheskaya khimiya. M., 1985. T. 8. - S. 429-488; T. 9. - S. 442-457.

3. Zhilkrist T. Khimiya geterotsiklicheskikh soedinenii. M., 199b.

4. Dzhoul' Dzh., Smit G. Osnovy khimii geterotsiklicheskikh soedinenii. M., 1975.

5. Konoplya N. E. // Dokl. HAH Belarusi. 2009. T. 53, № 2. S. 91-94.

6. Mashkovskii M. D. Lekarstvennye sredstva. M., 1984.

7. Laboratornye metody issledovaniya v klinike: spravochnik / V. V. Men'shikova (red.). M., 1987.

8. Sokolov S. D. // Uspekhi khimii. 1979, T. 48, № 3. S. 533-5b2.

9. Khimioterapiya zlokachestvennykh novoobrazovanii / redkol.: E. Chu, V. De Vita. M., 2008.

10. Alsina F. C., Ledda K., Paraticha G. // J. Neurochem. 2012. Vol. 123. P. b52-bb1.

11. Beebe J. S., Jani J. P., Knauth E. // Cancer Res. 2003. Vol. b3. P. 7301-7309.

12. Bavcar S., Argyle D. J. // Veterenary and Comparative Oncol. 2012. Vol. 10, N 3. P. 1b3-173.

13. Chakravarti A., Wang M., Robins H. I. et al. // Int. J. Radiat. Oncol. Biol. Phys. 2012. Vol. S0360-3016, N 12. P. 03b58-03b59.

14. Grynberg N., Santos A. C., Echevarria A. // Anticancer Drugs. 1997. Vol. 8, N 1. P. 88-91.

15. Klein D. E, Nappin V. M., Reeves G. T. et al. // Nature. 2004. Vol. 430. P. 1040-1043.

16. Kulchitsky V. A., Talabaev M. V., Chernov A. N. et al. // Glioma - Exploring Its Biology and Practical Relevance. 2011. P. 4b5-48b.

17. Kulchitsky V. A., Potkin V. I., Zubenko Y. S. et al. // Med. Chemistry. 2012. Vol. 8. P. 22-32.

18. Lafay-Cousin L., Strother D. // The Oncologist. 2009. Vol. 14. P. 434-444.

19. Ledda F., Bieraugel O., Fard S. S. et al. // J. Neurosci. 2008. Vol. 28. P. 39-49.

20. MacDonald T. J., Brown K. E., La Fleur B. et al. // Nat. Gent. 2003. Vol. 29. P. 143-152.

21. MacNeill C. M., Wailes E. M., Levi-Polyachenko N. H. // J. Nanosci. Nanotechnol. 2013. Vol. 13, N 6. P. 3784-3791.

22. Mahboobi S., Sellmer A., Höcher H. et al. // J. Med. Chem. 2006. Vol. 49, N 19. P. 5769-5776.

23. Muralikrishna A., Venkatesh B. C., Padmavathi V. et al. // Eur. J. Med. Chem. 2012. Vol. 54. P. 605-614.

24. Ohira Y., Inoue N. // Biochim. Biophys. Acta. 1995. Vol. 1243. P. 367-372.

25. Potkin V. I., Petkevich S. K., Zubenko Yu. S. et al. // Biologically active substances: fundamental and applied problems: abstracts of scientific conference. Novy Svet, May 23-28, 2011. P. 156.

26. Purohit M. N., Chandrashekhar V. M., Mayur Y. C. // Med. Chem. 2012. Vol. 18. P. 220-243.

27. Rademaker-Lakhai J. M., Crul M., Zuur L. et al. // J. Clin. Oncol. 2006. Vol. 24, N 6. P. 918-924.

28. Robertson P. L. // Amer. Soc. Exper. Neuro Therapeutic Ins. 2006. Vol. 3. P. 276-291.

29. Sandberg A. A., Stone N. // Humana Press, Totowa. NY, 2008. Ch. 8. P. 343-430.

30. Shi F., Zeng X. N., Cao X. D. et al. // Bioorg. Med. Chem. Lett. 2012. Vol. 22, N 1. P. 743-746.

31. Tremont-Laicas I. W., Gilbert M. B. // Cancer Control. 2003. Vol. 10. P. 125-137.

32. Vacchelli E. // Oncoimmunology. 2012. Vol. 1, N 2. P. 179-188.

33. Vega J. A., Garcia-Suarez O., Hannestad J. et al. // J. Anat. 2003. Vol. 203. P. 1-19.

34. Viale M., Anzaldi M., Aiello C. et al. // Pharmacol. Rep. 2013. Vol. 65, N 3. P. 717-723.

35. Wang M., Tan W., Zhou J. et al. // J. Biol. Chem. 2008. Vol. 283. P. 18678-18684.

36. Yoshida N., Kiyohara T., Fukui M. et al. // Cancer Res. 1980. Vol. 40, N 10. P. 3810-3814.

For citations:

Chernov A.N., Pozdniak L.V. Cytotoxic effects of 4-{3-[5-(n-tolyl)isoxazol-3-yl)ureido)butanoic acid, cisplatin and their combination in vitro and in vivo. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2014;(2):74-80. (In Russ.)

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1814-6023 (Print)
ISSN 2524-2350 (Online)

Proceedings of the National Academy of Sciences of Belarus, Medical series

Cytotoxic effects of 4-{3-[5-(n-tolyl)isoxazol-3-yl)ureido)butanoic acid, cisplatin and their combination in vitro and in vivo

Full Text:

Abstract

About the Authors

References

Review

For citations:

Username
Password
	Remember me

User

Proceedings of the National Academy of Sciences of Belarus, Medical series

Cytotoxic effects of 4-{3-[5-(n-tolyl)isoxazol-3-yl)ureido)butanoic acid, cisplatin and their combination in vitro and in vivo

Full Text:

Abstract

About the Authors

References

Review

For citations:

Cookies policy